Jakavi Euroopan unioni - suomi - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinibi (fosfaatteina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiset aineet - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polysytemia vera (pv)jakavi on tarkoitettu aikuisille potilaille, joilla on polysytemia vera, jotka ovat resistenttejä tai intolerantteja ja hydroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Opzelura Euroopan unioni - suomi - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

JAKAVI 5 mg Resepti Suomi - suomi - Fimea (Suomen lääkevirasto)

jakavi 5 mg resepti

tabletti - l01xe18 ruksolitinibi [näytä works saman ryhmän lääkevalmisteet] - resepti - 5 mg

Inrebic Euroopan unioni - suomi - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiset aineet - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Sunitinib Sandoz 12.5 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib sandoz 12.5 mg kapseli, kova

sandoz a/s - sunitinib - kapseli, kova - 12.5 mg - sunitinibi

Sunitinib Sandoz 25 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib sandoz 25 mg kapseli, kova

sandoz a/s - sunitinib - kapseli, kova - 25 mg - sunitinibi

Sunitinib Sandoz 37.5 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib sandoz 37.5 mg kapseli, kova

sandoz a/s - sunitinib - kapseli, kova - 37.5 mg - sunitinibi

Sunitinib Sandoz 50 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib sandoz 50 mg kapseli, kova

sandoz a/s - sunitinib - kapseli, kova - 50 mg - sunitinibi

Sunitinib Ratiopharm 12.5 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib ratiopharm 12.5 mg kapseli, kova

ratiopharm gmbh - sunitinib - kapseli, kova - 12.5 mg - sunitinibi

Sunitinib Ratiopharm 25 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

sunitinib ratiopharm 25 mg kapseli, kova

ratiopharm gmbh - sunitinib - kapseli, kova - 25 mg - sunitinibi